- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02058901
Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
A Phase I Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
The primary objective of this study is:
- To determine the maximum tolerated dose (MTD) of sunitinib when administered once weekly or once every two weeks.
- To assess the safety and tolerability of sunitinib in a once weekly or once every two weeks dose schedule.
Visão geral do estudo
Descrição detalhada
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Amsterdam, Holanda, 1081HV
- VU University Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Signed (by the patient or legally acceptable representative) and dated Informed Consent Form
- Histological or cytological documentation of incurable locally advanced or metastatic solid malignancy for which no standard therapy exists.
- Primary tumor or metastatic site must be accessible for biopsy. Patients eligible for the expansion cohort must be willing to undergo tumor biopsies, while tumor biopsy remains optional for patients enrolled in the escalation cohort. Bone metastases are excluded as a biopsy site.
- Evaluable disease by RECIST version 1.1 criteria (see appendix III; at least 1 target or non-target lesion for dose escalation cohorts; at least 1 target lesion for dose expansion cohort).
- Patients must have documented radiographic or clinical progressive disease.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Normal 12-lead ECG (clinically insignificant abnormalities permitted), and Left Ventricular Ejection Fraction (LVEF) > 50% by multigated acquisition (MUGA) scan or echocardiogram.
- Normal regulated thyroid function- suppletion or blocking drugs permitted.
- Urinalysis: no clinically significant abnormalities.
Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to screening:
- Hemoglobin >= 5.6 mmol/l
- Absolute neutrophil count (ANC) >=1,5 x 10*9/l
- Platelet count >= 100 x 10*9/l
- Total bilirubin <=1.5 times the upper limit of normal (ULN)
- ALT and AST 2.5 x ULN (In case of liver metastases: < 5 x ULN)
- Alkaline phosphatase < 4 x ULN
- Serum creatinine <= 1.5 x ULN or Creatinine clearance >= 50 ml/min (based on MDRD)
- PT-INR/PTT < 1.5 x ULN, unless coumarin derivatives are used
- Activated partial thromboplastin time < 1.25 x ULN (therapeutic anticoagulation therapy is allowed, if this treatment can be interrupted for a biopsy as judged by the treating physician)
- Patients with known Gilbert's disease who have serum bilirubin <= 3x ULN may be enrolled.
- Pregnant or breast-feeding subjects: Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. For fertile men or women of childbearing potential: documented willingness to use a highly effective means of contraception (e.g., hormonal methods [implants, injectables, or combined oral contraceptives], intrauterine devices, sexual abstinence, or vasectomized or surgically sterilized partner). Contraception is necessary for at least 6 months after receiving the study kinase inhibitor.
Exclusion Criteria:
- Evidence of a significant uncontrolled concomitant disease, such as cardiovascular disease (including stroke, New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to screening, unstable arrhythmia, clinically significant valvular heart disease and unstable angina); nervous system, pulmonary (including obstructive pulmonary disease and history of symptomatic bronchospasm), renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture.
- Poorly controlled hypertension despite adequate blood pressure medication. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen. Blood pressure must be stable on at least 2 separate measurements.
- Seizure disorders requiring anticonvulsant therapy.
- jor surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery.
- Known active bacterial, viral, fungal, mycobacterial, or other infection (including HIV and atypical mycobacterial disease, but excluding fungal infection of the nail beds.)
- Known hypersensitivity to sunitinib or to its excipients.
- Presence of any significant central nervous system or psychiatric disorder(s) that would interfere with the patient's compliance.
- Drug or alcohol abuse.
- Females who are pregnant or breast-feeding.
- Any evidence of a disease or condition that might affect compliance with the protocol or interpretation of the study results or render the patient at high risk from treatment complications.
- Unwillingness or inability to comply with study and follow-up procedures.
- No chemotherapy, radiotherapy, or biologic therapy within the previous 4 weeks; no nitrosoureas or mitomycin C within the previous 6 weeks; no investigational agents within the previous 4 weeks.
- Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
- Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control);
Patients with a history of treated CNS metastases are eligible, provided that all of the following criteria are met:
- Presence of evaluable or measurable disease outside the CNS
- Radiographic demonstration of improvement upon completion of CNS-directed therapy and no evidence of interim progression between completion of CNS-directed therapy and the screening radiographic study
- Completion of radiotherapy ≥ 8 weeks prior to the screening radiographic study
- Discontinuation of corticosteroids and anticonvulsants ≥ 4 weeks prior to the screening radiographic study.
Note: Prior sunitinib therapy does not constitute an exclusion criterion.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição fatorial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Sunitinib high dose, weekly schedule
Initial dose of sunitinib is set at 200 mg once weekly.
Three patients are treated at the current dose level.
If at least 2 patients are observed to have Dose Limiting Toxicity (DLT), the prior dose level is defined as the Maximum Tolerated Dose (MTD) (unless only 3 patients have been treated at that level, in which case it is the tentative MTD).
If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort of 3 patients.
If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level.
If none of these show DLT, the dose level is escalated for the next cohort of 3 patients; otherwise, the prior dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD).
A tentative MTD becomes final when a total of 6 patients are treated with less than 2 showing DLT
|
|
Experimental: Sunitinib high dose, biweekly schedule
When the final MTD is reached for the cohort of patients treated once weekly and depending on the toxicities developed and defining MTD, enrollment of patients in the once every 2 weeks escalation cohort will begin, with the initial dose set at the MTD dose of the once weekly schedule, escalating again at 100 mg increments per dose level.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
maximum tolerated dose (MTD) of sunitinib
Prazo: 6 weeks
|
6 weeks
|
Number of participants with serious and non-serious adverse events
Prazo: 6 weeks
|
6 weeks
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
Calculation of maximum plasma drug concentration, sunitinib half life, Area Under the Concentration-Time Curve (AUC 0-48h), clearance and volume of distribution
Prazo: Prior to the initial dose on day 1 and 2, 4, 6, 8, 10, 24, and 48 hours post-dose
|
Prior to the initial dose on day 1 and 2, 4, 6, 8, 10, 24, and 48 hours post-dose
|
Time to Disease Progression
Prazo: end of study
|
end of study
|
Recommended phase II dose (RP2D) and the optimal dose schedule
Prazo: End of study
|
End of study
|
Measurement of intratumoral and skin concentration of sunitinib
Prazo: 2 weeks
|
2 weeks
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2013/75
- 2012-005756-41 (Número EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Tumores Sólidos
-
Sorrento Therapeutics, Inc.RetiradoTumor Sólido | Tumor Sólido Recidivante | Tumor Refratário
-
Aadi Bioscience, Inc.RecrutamentoTumor Sólido Avançado | Tumor | Tumor SólidoEstados Unidos
-
Memorial Sloan Kettering Cancer CenterRecrutamentoTumor Sólido | Tumor Sólido, Adulto | Tumor Sólido, Não Especificado, AdultoEstados Unidos
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecrutamentoTumor Sólido | Tumor Sólido, Adulto | Tumor Sólido, Não Especificado, AdultoEstados Unidos, Porto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecrutamentoTumor Sólido | Tumor Sólido, Adulto | Tumor Sólido, Não Especificado, AdultoEstados Unidos, Porto Rico
-
RemeGen Co., Ltd.ConcluídoTumor Sólido Metastático | Tumor Sólido Localmente Avançado | Tumor sólido irressecávelAustrália
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyAtivo, não recrutandoTumor de Mutação Positiva PD-L1 | Tumor de Mutação Positiva EBV | Tumor Mutação MSI-H | Tumor de mutação POLE/POLD1Republica da Coréia
-
National Health Research Institutes, TaiwanNational Cheng-Kung University HospitalRecrutamento
-
Elpiscience Biopharma, Ltd.Shanghai Junshi Bioscience Co., Ltd.RecrutamentoNeoplasias | Tumor Sólido | Tumor malignoChina
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyRecrutamentoTumor Sólido, Adulto | Tumor RefratárioEstados Unidos
Ensaios clínicos em Sunitinibe
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)RescindidoTumor Sólido Adulto Não Especificado, Protocolo Específico | Câncer metastático | Efeitos cognitivos/funcionaisEstados Unidos
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)ConcluídoCancêr de rinsEstados Unidos
-
University of Alabama at BirminghamPfizerRescindido
-
PfizerConcluídoTumores Estromais Gastrointestinais
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.ConcluídoCarcinoma de Células Renais | Tumores Estromais Gastrointestinais | Tumor Neuroendócrino PancreáticoChina
-
AGO Study GroupPhilipps University Marburg Medical Center; HSK Reasearch GmbH WiesbadenConcluídoCâncer de ovário epitelial refratário à platina | Câncer Primário do Peritônio | Câncer das Trompas de FalópioAlemanha
-
Duke UniversityPfizerConcluído
-
Amsterdam UMC, location VUmcVitrOmics BVRescindidoTumores Sólidos Avançados | Metástase | InoperávelHolanda
-
Washington University School of MedicinePfizerConcluídoCâncer de Pulmão de Células Não PequenasEstados Unidos
-
Hadassah Medical OrganizationDesconhecidoCâncer de Células Renais